End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,029 INR | +2.19% | +2.91% | +20.88% |
May. 22 | Metropolis Healthcare Limited to Seek Acquisitions | CI |
May. 22 | Transcript : Metropolis Healthcare Limited, Q4 2024 Earnings Call, May 22, 2024 |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 76.89 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.88% | 1.22B | B+ | ||
-22.94% | 7.77B | B+ | ||
+75.84% | 4.51B | C+ | ||
+6.87% | 2.76B | B- | ||
-2.63% | 2.67B | - | ||
-49.74% | 2.09B | B- | ||
-18.48% | 1.72B | C- | ||
-19.46% | 1.49B | A- | ||
-45.82% | 1.12B | C+ | ||
+20.68% | 1.05B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- METROPOLIS Stock
- Ratings Metropolis Healthcare Limited